P53 Therapeutics is a biotechnology company headquartered in Philadelphia, Pennsylvania that develops small‑molecule cancer therapeutics aimed at bypassing or restoring the function of the mutated p53 tumor‑suppressor gene. The company focuses on precision oncology, genomic medicine, and strategies to overcome drug resistance, advancing a pipeline of innovative treatments through collaboration with academic and industry partners.
No recent news for this company.